B-cell Lymphoma Refractory
B-cell lymphoma refractory is a type of cancer where the B-cells, which are part of the immune system, do not respond to standard treatments. This condition can lead to a variety of symptoms and requires specialized care.
B-Cell Lymphoma: KITE-363 and KITE-753 Study
We are investigating the safety and dosing of two new drugs for individuals with relapsed or refractory B-cell lymphoma. This study aims to gather important information to improve treatment options.
Safety phase (I)Oncology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Wuerzburg AöR
Medizinische Klinik Und Poliklinik II
Würzburg, Germany
Amsterdam UMC Stichting
Clinical Hematology
Amstelveen, Netherlands
Sponsor: Kite Pharma Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.